NCT00116844 - VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2005

Primary Completion Date

January 10, 2006

Study Completion Date

January 10, 2006

Conditions

Infections, Herpesviridae

Interventions

DRUG

Valaciclovir

Valtrex 1g once daily

DRUG

Placebo

placebo

Trial Locations (17)

10011

GSK Investigational Site, New York

10029

GSK Investigational Site, New York

10461

GSK Investigational Site, The Bronx

11794

GSK Investigational Site, Stony Brook

27599

GSK Investigational Site, Chapel Hill

46202

GSK Investigational Site, Indianapolis

46804

GSK Investigational Site, Fort Wayne

74104

GSK Investigational Site, Tulsa

77030

GSK Investigational Site, Houston

84132

GSK Investigational Site, Salt Lake City

92506

GSK Investigational Site, Riverside

92585

GSK Investigational Site, Sacramento

95608

GSK Investigational Site, Carmichael

95616

GSK Investigational Site, Davis

97210

GSK Investigational Site, Portland

98104

GSK Investigational Site, Seattle

02115

GSK Investigational Site, Boston